Localization of MPP+ binding sites in the brain of various mammalian species
暂无分享,去创建一个
A. Albanese | M. Zompo | M. Morelli | M. Piccardi | S. Ruiu
[1] M. Herkenham,et al. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: An in vivo autoradiographic study , 1991, Neuroscience.
[2] M. Zompo,et al. [3H]1‐Methyl‐4‐Phenyl‐2,3‐Dihydropyridinium Ion Binding Sites in Mouse Brain: Pharmacological and Biological Characterization , 1990, Journal of neurochemistry.
[3] R. Olsen,et al. MPTP is proconvulsant acutely but has no long-term effect in rodent models of seizure and epilepsy , 1989, Brain Research.
[4] R. Fariello,et al. MPTP and convulsive responses in rodents , 1987, Brain Research.
[5] R. Cohen,et al. MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons. , 1987, European journal of pharmacology.
[6] R. Maggio,et al. High affinity binding sites for 1-methyl-4-phenyl-pyridinium ion (MPP+) are present in mouse brain. , 1986, European journal of pharmacology.
[7] U. Bonuccelli,et al. Involvement of monoamine oxidase enzymes in the action of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine, a selective neurotoxin, in the squirrel monkey: Binding and biochemical studies , 1986, Brain Research.
[8] S. Snyder,et al. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP+ binds to neuromelanin. , 1986, Science.
[9] A. J. Bradbury,et al. 1-Methyl-4-phenylpyridine is neurotoxic to the nigrostriatal dopamine pathway , 1986, Nature.
[10] R. Fuller,et al. Influence of selective, reversible inhibitors of monoamine oxidase on the prolonged depletion of striatal dopamine by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. , 1985, Life sciences.
[11] M. Zompo,et al. 1 ‐Methyl‐4‐Phenyl‐ 1,2,3,6‐Tetrahydropyridine: Correspondence of Its Binding Sites to Monoamine Oxidase in Rat Brain, and Inhibition of Dopamine Oxidative Deamination In Vivo and In Vitro , 1985, Journal of neurochemistry.
[12] S. Snyder,et al. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[13] B. Parsons,et al. Localization in rat brain of binding sites for parkinsonian toxin MPTP: similarities with [3H]parygyline binding to monoamine oxidase , 1985, Brain Research.
[14] M. Dubocovich,et al. Quantitative autoradiography of 3H-nomifensine binding sites in rat brain. , 1985, Life sciences.
[15] M. Yahr,et al. Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. , 1984, European journal of pharmacology.
[16] R. S. Burns,et al. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism , 1984, Nature.
[17] R. Duvoisin,et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.
[18] T. Hökfelt,et al. Chemical anatomy of the brain. , 1984, Science.
[19] K. Chiba,et al. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. , 1984, Biochemical and biophysical research communications.
[20] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[21] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[22] R. Schwarcz,et al. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.
[23] Dr. Heinz Stephan,et al. The Brain of the Common Marmoset (Callithrix jacchus) , 1980, Springer Berlin Heidelberg.
[24] Sanford P. Markey,et al. Chronic parkinsonism secondary to intravenous injection of meperidine analogues , 1979, Psychiatry Research.
[25] J. Glowinski,et al. Topographical distribution of dopaminergic innervation and of dopaminergic receptors in the rat striatum. I. Microestimation of [3H]dopamine uptake and dopamine content in microdiscs , 1976, Brain Research.
[26] A. Herbet,et al. Specificity of dopaminergic neuronal degeneration induced by intracerebral injection of 6-hydroxydopamine in the nigrostriatal dopamine system , 1976, Brain Research.
[27] M. Dubocovich,et al. Autoradiographic Visualization and Quantification of Dopamine Receptors and Uptake Sites in the Rat and Human CNS , 1986 .
[28] D. Jacobowitz,et al. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. , 1984, Psychopharmacology bulletin.
[29] G. Paxinos,et al. The Rat Brain in Stereotaxic Coordinates , 1983 .
[30] W. Greenough,et al. A stereotaxic atlas of the albino mouse forebrain. , 1980 .
[31] L. Pellegrino,et al. stereotaxic atlas of the rat brain , 1967 .